FDA Crackdown on Compounded GLP-1: Patient Impact Guide
Understanding the FDA's enforcement actions against compounded GLP-1 medications. What patients need to know, how to protect yourself, and options if your compounded supply is affected.
More on GLP-1 News
Patient Alert
The FDA has intensified enforcement against compounding pharmacies producing GLP-1 medications. This affects millions of patients who rely on compounded semaglutide and tirzepatide for affordable access. If you use compounded GLP-1 medication, read this guide and discuss contingency plans with your provider.
What Is Happening
As brand-name GLP-1 supply has improved, the FDA has been reassessing shortage designations that allowed compounding pharmacies to produce semaglutide and tirzepatide. When a medication is removed from the FDA's Drug Shortage List, compounding pharmacies lose their primary legal basis for producing it.
The FDA has sent warning letters and cease-and-desist notices to numerous compounding pharmacies, issued public warnings about specific products, and increased inspections of compounding facilities. Several pharmacies have voluntarily stopped compounding GLP-1 medications in response.
This situation is complicated by ongoing litigation (the compounding antitrust lawsuit), state-level regulatory differences, and genuine questions about whether brand-name supply truly meets demand. The regulatory landscape is evolving rapidly.
The Legal Landscape
When compounding IS legal
- The medication is on the FDA Drug Shortage List
- A patient has a specific medical need not met by commercial products (e.g., allergy to an inactive ingredient)
- The pharmacy holds proper 503A or 503B registration
- A valid patient-specific prescription exists
When compounding is NOT legal
- The medication is no longer on the shortage list and no patient-specific need exists
- The pharmacy is essentially manufacturing and distributing without FDA approval
- Products are sold without valid prescriptions or medical evaluations
- Products are marketed using brand names (Wegovy, Ozempic, etc.)
What Patients Should Do Now
Step 1: Do not panic. Even if regulatory changes are coming, they typically include transition periods. You will not lose access overnight.
Step 2: Talk to your provider about a backup plan. Explore insurance coverage for brand-name medications, manufacturer savings programs, and dose adjustment strategies.
Step 3: Verify your compounding pharmacy's credentials. PCAB accreditation, state licensure, and third-party testing are minimum standards. Our compounding safety guide provides detailed criteria.
Step 4: Check your insurance coverage. With employer coverage expanding and Medicare adding GLP-1 benefits, you may have options you did not have when you started compounded medication.
Step 5: Build a medication buffer. If your compounded supply is currently available, ensure you do not wait until the last day to refill. Having a few weeks of buffer prevents gaps if supply is interrupted.
Medical Disclaimer: This article is for educational purposes only and does not constitute legal or medical advice. Compounding regulations vary by state and are evolving. Consult your healthcare provider and a qualified legal professional for guidance specific to your situation.
Frequently Asked Questions
Is compounded semaglutide now illegal?
Not necessarily. Compounding pharmacies can legally compound medications that are on the FDA shortage list or for which there is a medical need that commercial products cannot meet. However, as brand-name supply stabilizes, the legal basis for compounding weakens, and FDA enforcement increases.
What should I do if my compounding pharmacy closes?
Contact your prescribing provider immediately to discuss transitioning to brand-name medication. Ask about manufacturer savings programs, insurance coverage options, and dose-equivalent switching protocols. Do not abruptly stop GLP-1 medication without medical guidance.
How can I tell if my compounding pharmacy is reputable?
Look for PCAB accreditation (or equivalent state certification), verify they have a licensed pharmacist on staff, check that they require a valid prescription, confirm they use USP-grade semaglutide, and verify they perform third-party purity testing. Be wary of pharmacies that do not require a prescription or medical evaluation.
Will compounded GLP-1 medications disappear completely?
The future of compounded GLP-1 depends on ongoing litigation, FDA shortage designations, and potential legislative action. The compounding antitrust lawsuit may affect outcomes. Patients should plan for the possibility of needing to transition to brand-name products.
Navigate Your GLP-1 Options
Our team helps you find the safest, most affordable GLP-1 access path regardless of regulatory changes.
Consult with a ProviderSources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).